Laropiprant attenuates EP3 and TP prostanoid receptor-mediated thrombus formation. [electronic resource]
Producer: 20130219Description: e40222 p. digitalISSN:- 1932-6203
- Blood Coagulation -- drug effects
- Blood Platelets -- cytology
- Calcium -- metabolism
- Dyslipidemias -- drug therapy
- Female
- Gene Expression Regulation -- drug effects
- Humans
- Hypolipidemic Agents -- therapeutic use
- Indoles -- pharmacology
- Male
- Niacin -- therapeutic use
- P-Selectin -- biosynthesis
- Platelet Aggregation -- drug effects
- Platelet Glycoprotein GPIIb-IIIa Complex -- biosynthesis
- Prostaglandin D2 -- metabolism
- Receptors, Prostaglandin E, EP3 Subtype -- biosynthesis
- Thrombosis -- metabolism
No physical items for this record
Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.